TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04590482
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo given twice daily for 2 days followed by 800mcg misoprostol vaginally to induce abortion
Study: NCT01675167
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo Buccal Film twice daily
Study: NCT00167219
Drug: Preparative Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Busulfan~* Cyclophosphamide~* Mesna~* Melphalan~* Anti-thymocyte Globulin (ATG)
Study: NCT01152931
Drug: Lumefantrine + Artemether
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumefantrine and artemether combination will be administered orally at a dose of 120/20mg daily for 3days
Study: NCT00594568
Drug: LY450139
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally once daily
Study: NCT00594568
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally once daily
Study: NCT01440608
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill form, 400 mg dose to be given once per day for 14 days in Placebo arm and 13 days in Albendazole arm following one dose of Albendazole.
Study: NCT03140813
Drug: AZD7325 (High-Dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15mg PO BID
Study: NCT03140813
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be dosed similar to AZD7325, in terms of dosage form, frequency and duration.
Study: NCT02042872
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: At baseline, study subjects in the treatment group will receive 5 mg of zoledronic acid (Reclast: 5 mg; Novartis Pharmaceuticals Inc., East Hanover, NJ) by intravenous infusion over 30 minutes.
Study: NCT02103673
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention drug: placebo by mouth. Duration: 6 weeks
Study: NCT03696459
Drug: JNJ-53718678, 2000 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered JNJ-53718678, 2000 mg as oral suspension in Part 1 (Panel 1).
Study: NCT03696459
Drug: JNJ-53718678, 3000 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered JNJ- 53718678, 3000 mg as oral suspension in Part 1 (Panel 2).
Study: NCT03696459
Drug: JNJ-53718678, 4500 mg or Dose to be decided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered JNJ-53718678, 4500 mg as oral suspension in Part 1 (Panel 3). If this dose is considered safe and tolerable and if pharmacokinetic data require further dose escalation, then participants will receive JNJ-53718678 (Dose to be decided) in Part 1 (Panel 4). This dose (either from Panel 3 or Panel 4 ) will be used in Part 2 (Dose may be lower/higher based on review of safety, tolerability, and PK data obtained in Part 1).
Study: NCT03696459
Drug: JNJ-53718678 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered JNJ-53718678 matching placebo in Part 1 and 2.
Study: NCT01214096
Drug: rhNRG-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Administration:0.6ug/kg/day for 10days
Study: NCT02487459
Drug: AP1903
Approvals — FDA: no, EMA: no, PMDA: no
Description: dimerizer drug administered to treat GVHD
Study: NCT01214096
Drug: rhNRG-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Administration 1.2ug/kg/day for 10 days
Study: NCT01214096
Drug: rhNRG-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vein infusion:0.6ug/kg/day for 10 days
Study: NCT01214096
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Administration:0.6 or 1.2ug/kg/day for 10days
Study: NCT01574183
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: up to 40 mg capsule daily
Study: NCT02515175
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Normal Saline
Study: NCT01556659
Drug: Absence of vitamin K antagonist
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual anti-platelet therapy
Study: NCT01180634
Drug: Aeroquin
Normalized name: Enroquin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation Solution
Study: NCT01180634
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation Solution
Study: NCT02482818
Drug: Control-Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A control substance, Lactose is administered in place of Pregabalin.
Study: NCT02712047
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will have two blister strips, identical in appearance to the inhaler containing active study medication; one containing lactose and the second strip containing lactose and magnesium stearate
Study: NCT00826462
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection with sodium chloride at start and at 3 weeks
Study: NCT00826462
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen 500 mg bid for 14 days
Study: NCT02145949
Drug: Placebo (Alanine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily ingestion of 20 or 23 grams Placebo (alanine) for 7 days leading up to surgery and continuing for 6 weeks after surgery \[surgery = primary total knee arthroplasty\]
Study: NCT00153751
Drug: Holopon
Approvals — FDA: no, EMA: no, PMDA: no
Description: holopon
Study: NCT00436345
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: analgesia in medical and post-surgical Intensive Care Unit subjects requiring mechanical ventilation
Study: NCT03609606
Drug: D013, D326 and D337
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral administration of 1 tablet for each drug under fasting conditions for 7 days
Study: NCT04222010
Drug: Loco-regional anesthesia : paravertebral bloc (Ropivacaine 4 mg/mL, 20 mL) and serratus plane placebo bloc (saline, 40 mL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient who underwent thoracoscopic surgery will be assigned to one procedure of Loco-regional anesthesia.
Study: NCT04222010
Drug: Loco-regional anesthesia : serratus plane bloc (Ropivacaine 1,3 mg/mL, 40 mL) and paravertebral bloc (Ropivacaine 1,3 mg/mL, 20 mL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient who underwent thoracoscopic surgery will be assigned to one procedure of Loco-regional anesthesia.
Study: NCT00103376
Drug: Androgen Receptor Antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: given orally daily for 3 months
Study: NCT04726631
Drug: regular insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: is a type of short-acting insulin.
Study: NCT01296672
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo every day by mouth for 3 months
Study: NCT01464060
Drug: PPI, amoxicillin, metronidazole and clarithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy for 7 days: 40 mg omeprazole and 1g amoxicillin every 12h. After dual therapy continue with a quadruple therapy for 7 days: 40 mg omeprazole, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h.
Study: NCT01464060
Drug: PPI, amoxicillin, metronidazole and clarithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy for 14 days: 40 mg omeprazole, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h
Study: NCT03378713
Drug: GROUP 1: Long testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of testosterone in transdermal gel during the 2 cycles prior to initiation of controlled ovarian stimulation and until the onset of second menstruation (approximately 56 days). The COS begins the day after the last testosterone application
Study: NCT03378713
Drug: GROUP 2: Short testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of testosterone in transdermal gel begins on day 21 of menstrual cycle, from the luteal phase of the cycle prior to initiation of controlled ovarian stimulation and until menstruation (approximately 10 days). The COS begins the day after the last testosterone application.
Study: NCT01568255
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo at 50,000IU for 8 weeks
Study: NCT03047889
Drug: standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard therapy for advanced/metastatic breast cancer
Study: NCT00250965
Drug: intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomized prior to surgery (1:1) to receive 5 g magnesium or placebo (saline) bolus by the anaesthesiologist upon removal of the crossclamp. On postoperative days 1 through 4, subjects will receive either IV MgSO4 (5g in 250 ml normal saline) or IV placebo (250 ml normal saline) infusion over 4 hours daily.
Study: NCT03378713
Drug: GROUP 3: Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: The COS starts directly on the second day of the cycle without prior medication.
Study: NCT03106740
Drug: Minocycline Hydrochloride 100mg Capsule
Normalized name: minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline 100mg will be administered by mouth daily for 2 weeks
Study: NCT00093379
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 825 mg/m\^2 orally twice a day (BID), Mon-Fri during weeks 1, 2, 4, and 5.
Study: NCT00888186
Drug: levodopa/carbidopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: intestinal gel, for continuous daytime infusion
Study: NCT00133003
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo consist of placebo bolus and infusion of 12 hours (NaCl 0.9%), plus heparin bolus, 140 U/kg of body weight
Study: NCT03082625
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01790997
Drug: DLBS1033
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of DLBS1033 490 mg thrice daily, after meal
Study: NCT00694148
Drug: NT 201
Normalized name: Fluarix Quadrivalent 2013-2014
Approvals — FDA: no, EMA: no, PMDA: no
Description: A Botulinum neurotoxin type A, free of complexing proteins~Detailed described in study protocol
Study: NCT04402944
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 2.5 mL BID
Study: NCT04209166
Drug: SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors.
Study: NCT04209166
Drug: SSRIs/SNRIs+Mood Stabilizer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with Mood Stabilizer combined with Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors.
Study: NCT01548573
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01548573
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or PO
Study: NCT02751372
Drug: BAY 987517
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 μl/cm\*2 or 0.05 gm/cm\*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each). After the test articles have dried for 5 to 15 min, the sites are covered by the appropriate patch.24 hours later, the set of patches covering the product are removed. Three (3) μl/ cm2 or 0.003 gm/cm\*2 of the test product is reapplied to the test site, air dried for 5 to 15 minutes for volatilization and then the test site is exposed to UVA radiation.
Study: NCT00326339
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo PO bid
Study: NCT01694407
Drug: Placebo Vaginal Tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal Tablet containing no drug
Study: NCT00459186
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily for two weeks
Study: NCT00795210
Drug: Growth Hormone Releasing Hormone
Normalized name: Growth hormone releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tesamorelin (GHRH) 2mg SC QD x 2 weeks
Study: NCT00974480
Drug: Tretinoin (Rejuva-A)
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tretinoin 0.025% cream.
Study: NCT03883841
Drug: Iron Sucrose Solution for Injection
Normalized name: iron sucrose Injection
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion of iron sucrose
Study: NCT00709865
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV
Study: NCT05709938
Drug: Glargine and regular insulin versus NPH and regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with type 1 diabetes (T1DM) in group A received insulin glargine as basal therapy at night and regular insulin given prior to each main meal.~Patients in group B were given NPH and regular insulin in split and mix method in the morning and evening.
Study: NCT00144859
Drug: SB681323
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02920242
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo tablet administered orally
Study: NCT02802267
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT04462588
Drug: Cipro 400 MG in 200 ML Injection
Normalized name: Cipro 400 MG in 200 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: medical tratment group
Study: NCT04462588
Drug: Flagyl I.V. RTU
Normalized name: Flagyl I.V. RTU
Approvals — FDA: no, EMA: no, PMDA: no
Description: medical tratment group
Study: NCT03825861
Drug: FOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin 85mg/m2, Leucovorin 200mg/m2, Irinotecan 180mg/m2, 5-FU 400mg/m2 bolus followed by 2400mg/m2 continuous infusion.
Study: NCT02460601
Drug: Qizhiweitong granule
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00124709
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: conventional corticosteroid-based treatment
Study: NCT00122954
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: soybean oil with 1% fish oil at a daily dose of 6 grams
Study: NCT04135287
Drug: GLP-1 receptor agonist
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: The main objective of the study is to determine the relationship between the increase in glucose-stimulated insulin secretion and decrease in HbA1c caused by GLP-1 RA therapy in poorly controlled T2DM patients. We also will identify a cut point of an increase in beta cell function which produces a clinically meaningful decrease in HbA1c.
Study: NCT01988584
Drug: Saline Infusion (Placebo)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total of 10 children (5 from each cohort) will be randomized to a placebo infusion at the baseline visit and then have the opportunity to cross-over to stem cell treatment at the 1yr. visit.
Study: NCT01695759
Drug: Eprex
Normalized name: Eprex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants assigned to this arm will receive two subcutaneous administrations per week of 50 UI/kg of Epoetin alpha (Eprex), totaling 100 UI/kg/week. After the first four weeks of treatment, once a month throughout the study the medication dose can be adjusted by the study Investigator according to the laboratory results.
Study: NCT00759564
Drug: CP-70,429 and PF-03709270
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study Periods 1 and 2 will be separated by a minimum of 14 days. In Period 1, subjects will receive a single dose of CP-70429 (800 mg given as a 1.5 hour intravenous infusion), while in Period 2, subjects will receive a single oral dose of PF-03709270 (1000 mg).
Study: NCT03108846
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Masked placebo
Study: NCT04162301
Drug: CS3002
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS3002 tablet will be orally administered daily for 3 weeks followed by 1 week off treatment, defining a treatment cycle of 28 days in duration.
Study: NCT02961101
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy be given depends on the cancer type and treatment regimen before enrollment.
Study: NCT00520806
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion for 48 h
Study: NCT01728376
Drug: Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin, Semi-synthetic penicillin, First-generation cephalosporins, Clindamycin: administered per standard of care. Participants may be switched to oral therapy following completion of IV study drug administration provided they showed clear clinical improvement and the pathogen was susceptible to an oral agent.
Study: NCT01018810
Drug: LY2525623 Intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered intravenously at randomization and every 2 weeks for 6 weeks
Study: NCT01018810
Drug: LY2525623 Subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered subcutaneously at randomization and every 2 weeks for 6 weeks
Study: NCT01018810
Drug: Placebo Intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered intravenously at randomization and every 2 weeks for 6 weeks
Study: NCT01018810
Drug: Placebo Subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered subcutaneously at randomization and every 2 weeks for 6 weeks
Study: NCT04303065
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: The preparation and conditioning of the placebo capsules will be carried out following the standardized work procedures of the pharmaceutical laboratory and its quality controls, previously authorized by the Agencia Española del Medicamento (AEMPS).
Study: NCT02657408
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04749173
Drug: DWRX2003, 96mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Placebo Intramuscularly injection at predefined injection sites
Study: NCT04749173
Drug: DWRX2003, 144mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Placebo Intramuscularly injection at predefined injection sites
Study: NCT01009073
Drug: ABT-263
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-263 is taken orally.~Note - The dose and schedule is variable based on Arm and subject to change based on the toxicities observed.
Study: NCT01009619
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin 250 mg daily during 5 days followed by 250 mg three times a week on Mon., Wed. and Fri. during study-period.
Study: NCT01009619
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily during 5 days, followed by one placebo three times a week on Mon., Wed. and Fri during rest of study-period.
Study: NCT04044001
Drug: Rifafour e-275®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifafour e-275® (150mg rifampicin, 75mg isoniazid, 400mg pyrazinamide, 275 mg ethambutol per tablet)
Study: NCT01231880
Drug: Placebo given every month
Approvals — FDA: no, EMA: no, PMDA: no
Description: No active ingredient
Study: NCT00438568
Drug: Regular Insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered intra-nasally twice a day for 16 weeks
Study: NCT00438568
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered intra-nasally twice a day for 16 weeks
Study: NCT00136188
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral administration of folic acid 5mg /d for 4 weeks
Study: NCT00511368
Drug: matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04490915
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-active dosage form
Study: NCT01319565
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arm 1 and Arm 2 - Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 mL D5W with Mesna 15 mg/kg/day X 2 days over 1 hr.
Study: NCT02791763
Drug: 6 mg GSK1278863 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9.0 mm round, standard biconvex, white film coated tablets containing 6 mg of GSK1278863 as active ingredient, to be orally administered once daily.
Study: NCT02048319
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline solution, injected as placebo
Study: NCT00604760
Drug: Placebo for MEM 3454
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule once a day
Study: NCT00770159
Drug: Comparator: placebo to MK0822
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panel A: placebo to MK0822 tablets 25 mg once weekly for 3 weeks. Panel B: placebo to MK0822 tablets 50 mg once weekly for 3 weeks. Panel C: placebo to MK0822 tablets 100 mg once weekly for 3 weeks. Panel D: placebo to MK0822 tablets 5 mg once weekly for 3 weeks. Panel E: placebo to MK0822 tablets 100 mg once weekly for 6 weeks.
Study: NCT00302068
Drug: Placebo Pill.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill, daily, for 16 weeks.
Study: NCT02325206
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one administration in the morning
Study: NCT01032889
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate buffered saline placebo for injection
Study: NCT03204006
Drug: sterile saline
Normalized name: Aqua Care Sterile Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline preinduction
Study: NCT01489306
Drug: MDT-637
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled doses of MDT-637 over a 10 day period
Study: NCT03415711
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sachets with maltose, cornstarch and dioxide
Study: NCT01383148
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered starting on D1 of Cycle 1 of chemotherapy and will be administered weekly for 6 weeks by SC injections and then once every 3 weeks until progression or discontinuation due to any reason.~* First line therapy: as in Arm 1~* Maintenance therapy: as in Arm 1
Study: NCT03195309
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Compare different concentration of ropivacaine and fentanyl for elective Cesarean delivery post operative pain control.